Atara Biotherapeutics, Inc (ATRA) — Analysis Summary
Atara Biotherapeutics, Inc (ATRA) has a market cap of $78.12M with year-over-year revenue growth of -6.3%. Net margin stands at 27.1%. The stock trades at a P/E ratio of -8.3.
Key Takeaways
- Revenue changed -6.3% year-over-year
- Net margin of 27.1%
- P/E ratio of -8.3
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, ATRA posted revenue growth of -6.3% and trades at a P/E of -8.3.
Atara Biotherapeutics, Inc (ATRA)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -1.8x — earnings do not cover interest payments
Revenue fell 80.8% vs the prior period.
Net income turned negative after a profitable prior period.
Shareholder equity is negative, which can signal balance-sheet stress.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
13
Headquarters
THOUSAND OAKS, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.